J.J. Braun
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Vitamin D Research Studies, Parathyroid Disorders and Treatments, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension(2003)1,086 cited
- → Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group(2013)134 cited
- → INFLUENCE OF 1α‐(OH)D3 ADMINISTRATION ON BONE AND BONE MINERAL METABOLISM IN PATIENTS ON CHRONIC GLUCOCORTICOID TREATMENT; A DOUBLE BLIND CONTROLLED STUDY(1983)71 cited
- → A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG(2014)62 cited
- → Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).(2013)51 cited
- → SHORT‐TERM EFFECT OF PREDNISONE ON SERUM 1,25‐DIHYDROXYVITAMIN D IN NORMAL INDIVIDUALS AND IN HYPER‐AND HYPOPARATHYROIDISM(1982)42 cited
- → Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial(2014)31 cited
- → 671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)(2003)20 cited
- → LACK OF RESPONSE OF 1,25‐DIHYDROXYCHOLECALCIFEROL TO EXOGENOUS PARATHYROID HORMONE IN A PATIENT WITH TREATED PSEUDOHYPOPARATHYROIDISM(1981)10 cited
- → Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).(2013)3 cited